PGY2 SOT Edith Ford joins us from Mayo Clinic in Phoenix, Arizona to discuss "A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection", which has recently received Breakthrough Therapy Designation for ABMR in kidney transplant recipients, as well as a quick discussion on antibody-mediated rejection and CD38 inhibitors.